News

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Backlash Builds Over Biden Plan for Seizing Drug Patents

Agenda Setting: Bipartisan Push Back

Former officials combine forces to blast march-in rights

Public Comments Reveal Widespread Unity in Opposition to NIST’s March-In Rights Framework

WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies

KFF Health News: Morning Briefing

Iancu, Michel and Other PTAB Masters Panelists Float Ways to Make the System Better

The March-In Drug Price Control Narrative Crumbles While Its Damage to American Innovation Grows

Proposed ‘price’ criteria for march-in rights poses threat to U.S. innovation, critics say

Witnesses Clash Over Potential Pros and Cons of PERA in Senate IP Subcommittee Hearing

AI adds urgency to patent debate

Special council works to protect and promote STEM excellence